By Anne Cullen ( February 20, 2019, 1:20 PM EST) -- Bristol-Myers Squibb Co. has reset the clock for the Federal Trade Commission to wrap up its initial review of the pharmaceutical giant's planned $74 billion pick up of Celgene Corp., saying Wednesday that it has pulled and refiled the merger materials to "facilitate ongoing discussions."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.